Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07294534 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Name: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer — clinical trial record (NCT07294534)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorShanghai Henlius Biotech

Started2026-01-27

View on ClinicalTrials.gov ↗

Shanghai Henlius Biotech

56 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.

Trial Details

NCT Number	NCT07294534
Lead Sponsor	Shanghai Henlius Biotech
Conditions	HER2 + Breast Cancer
Enrollment	817 participants
Start Date	2026-01-27
Primary Completion	2028-09-30 (estimated)
Study Completion	2030-02-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-19